The Lawsuit Masking Takeda Cheap 9.8x Valuation
Takeda stock analysis: TAK trades at 9.8x Core EPS — buy or sell this deep-value pharma play? 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Takeda Pharmaceutical Co Ltd (TAK) and its massive pipeline pivot designed to offset the generic erosion of ADHD blockbuster Vyvanse. With shares trading at just 9.8 times trailing core earnings despite several highly competitive Phase 3 pipeline launches on the horizon, the key…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.